Jim Cramer -- BioMarin, Receptos Will Re-Test Highs, Biotech Will Recover

NEW YORK (TheStreet) -- Trading in the biotech sector has been "horrendous," TheStreet's Jim Cramer, portfolio manager of the Action Alerts PLUS portfolio, said Friday.

The iShares Nasdaq Biotechnology ETF (IBB) fell 6.2% on the week although the biotech exchange-traded fund rose 2.3% today.

Cramer said during CNBC's "Stop Trading" segment today's boost is thanks to two of his "four horsemen" -- Celgene (CELG), up 2%, and Gilead Sciences  (GILD), up nearly 5%. Both companies reported "inspiring" earnings results, Cramer said. 

IBB Chart
iShares Nasdaq Biotech ETF IBB data by YCharts

Cramer said two other biotechs look ready to re-test previous stock highs: BioMarin Pharmaceutical (BMRN), which he said has the best orphan drug pipeline and an "excellent" product portfolio, and Receptos (RCPT).

"Those are the two that I like very much," he said, adding that "biotech is not done" going higher.

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.

If you liked this article you might like

Illumina Lights the Way for Biotechs

Illumina Lights the Way for Biotechs

Indices Don't Have Much in Common

Trader's Daily Notebook: 3 ETFs With Healthy Setups

Trader's Daily Notebook: Keeping a Short Leash